In the United States, prostate cancer ranks first in terms of morbidity, and cancer, which ranks fourth in mortality, has afflicted American men. In particular, one of the metastatic castration-resistant prostate cancer (mCRPC) is even more terrible, with a five-year survival rate of only 28%. Immunotherapy, which is known as the new hope for cancer treatment, is currently not available for mCRPC. Phase II clinical trials (NCT02601014) indicate that CTLA-4/PD-1 antibodies do not have a significant effect on mCRPC.
At the beginning of March, Y. from the MD Anderson Cancer Research Center in the United States. Alan Wang and Ronald A. Professor DePinho's research team found that mCRPC has no response to immunotherapy and is closely related to the cancer cells' Myeloid-derived suppressor cells (MDSCs).
Y. Professor Alan Wang
They found that the use of existing CTLA-4/PD-1 antibodies while controlling the cells of the myeloid-inhibiting cells can achieve the efficacy of inhibiting mCRPC. This is to inhibit the MDSC drug and the existing CTLA-4/PD-1 antibody alone can not be achieved, only the two can be used together to achieve the inhibition of mCRPC [1]. Wang and Ronald A. The research results of the team of Professor DePinho were published in the journal Nature in late March. The first author of the article is Dr. Xin Lu, a Chinese scientist who was coached at the University of Notre Dame this year.
Professor Ronald DePinho said, "A large number of patients with advanced prostate cancer who have undergone androgen blockade therapy often relapse and become a deadly mCRPC. Although immune site inhibitor therapy has an effect on many cancers, it is special for this. The effectiveness of prostate cancer, immune site inhibitor therapy is less successful. This is why we are looking for specific therapies to overcome this problem."
What kind of sinister cancer is this refractory prostate cancer? First, prostate cancer cells rely heavily on testosterone for proliferation. A corresponding treatment is hormone therapy, which involves using drugs to limit the body's synthesis of testosterone or preventing testosterone from reaching the cancer cells, or surgically removing the testes. .
Dr. Xin Lu, a Chinese scientist who is currently teaching at the University of Notre Dame
Infusion Patch,Medical Infusion Patch,Medical Transfusion Patch,Disposable Infusion Sticker Patch
Henan Anbang Medical Supplies Co., Ltd. , https://www.anbangmedical.com